You are here

Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip

Last updated on May 12, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Aston Clinton, Bucks, GP22 5LB United Kingdom
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hip Osteoarthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
45+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosed with osteoarthritis of hip and requiring joint replacement

- Eligible for chronic therapy with an NSAID

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Hip surgery anticipated within 8 calendar weeks after first visit

- Active gastrointestinal disease or recent diagnosis of gastrointestinal ulceration
(within 60 days of first visit)

NCT00174317
Pfizer
Completed
Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Hip Osteoarthritis, Knee Osteoarthritis
NCT02709486
All Genders
18+
Years
Multiple Sites
Chronic Pain, Hip Osteoarthritis, Knee Osteoarthritis
NCT02528188
All Genders
18+
Years
Multiple Sites
Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip
Clinical Protocol For A Multicentre, Double-Blind, Randomised, Parallel Group Study To Compare The Efficacy and Tolerability Of Celecoxib Vs. Diclofenac In The Treatment Of Subjects With Osteoarthritis Of The Hip Requiring Joint Replacement Therapy
To determine if celecoxib 200 mg once daily is as effective as diclofenac 50 mg three times daily in the treatment of pain symptoms associated with osteoarthritis of the hip
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Osteoarthritis, Hip
  • Drug: Celecoxib
  • Drug: Diclofenac
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
250
February 2005
Not Provided

Inclusion Criteria:

  • Diagnosed with osteoarthritis of hip and requiring joint replacement
  • Eligible for chronic therapy with an NSAID

Exclusion Criteria:

  • Hip surgery anticipated within 8 calendar weeks after first visit
  • Active gastrointestinal disease or recent diagnosis of gastrointestinal ulceration (within 60 days of first visit)
Sexes Eligible for Study: All
45 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT00174317
COXA-0508-261
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2005

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now